Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
212M
-
Number of holders
-
177
-
Total 13F shares, excl. options
-
77.7M
-
Shares change
-
+3.24M
-
Total reported value, excl. options
-
$452M
-
Value change
-
+$17.4M
-
Put/Call ratio
-
0.63
-
Number of buys
-
78
-
Number of sells
-
-76
-
Price
-
$5.81
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q1 2022
219 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q1 2022.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 177 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 77.7M shares
of 212M outstanding shares and own 36.66% of the company stock.
Largest 10 shareholders include BlackRock Inc. (11.6M shares), WASATCH ADVISORS INC (10.6M shares), VANGUARD GROUP INC (10.1M shares), STATE STREET CORP (7.78M shares), CREDIT SUISSE AG/ (3.79M shares), DIMENSIONAL FUND ADVISORS LP (2.84M shares), GEODE CAPITAL MANAGEMENT, LLC (2.09M shares), JPMORGAN CHASE & CO (1.5M shares), Nuveen Asset Management, LLC (1.23M shares), and GOLDMAN SACHS GROUP INC (1.16M shares).
This table shows the top 177 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.